Treating HK-2 cells with the STING1 activator mtDNA and STING1 pcDNA could enhance the levels of PINK1 and parkin, which can reduce HK-2 cells damages exposed to HG (Zhu et al., 2023), which may provide an innovative therapeutic basis for DKD treatment. This evidence concerns the gene PRKN and diabetic kidney disease.